Detalhe da pesquisa
1.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med
; 376(2): 125-135, 2017 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28076709
2.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Eur J Nucl Med Mol Imaging
; 47(10): 2372-2382, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32123969
3.
Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.
Eur J Nucl Med Mol Imaging
; 36(8): 1265-72, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19266197
4.
Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors.
Cancer Biother Radiopharm
; 22(3): 374-81, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17651043
5.
Anticancer activity of targeted proapoptotic peptides.
J Nucl Med
; 47(1): 122-9, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16391196
6.
Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
J Med Chem
; 46(15): 3403-11, 2003 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-12852770
7.
Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents.
J Med Chem
; 45(10): 2003-15, 2002 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-11985468
8.
Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
J Nucl Med
; 43(12): 1650-6, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12468515
9.
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Pancreas
; 43(4): 518-25, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24632546
10.
Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
Bioconjug Chem
; 18(3): 724-30, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17378600
11.
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
Eur J Nucl Med Mol Imaging
; 30(6): 917-20, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12677301
12.
DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Bioconjug Chem
; 13(4): 721-8, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12121126
13.
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Eur J Nucl Med Mol Imaging
; 30(2): 312-5, 2003 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-12552352